LONDON, Nov 3 (Reuters) - GlaxoSmithKline said onTuesday it had the potential to file up to 20 new drugs forapproval before 2020 as it seeks to revitalise a portfolio hitby falling sales of best-selling inhaled lung treatment Advair.
Britain's biggest drugmaker is trying to boost low investorexpectations for its product pipeline by hosting its firstresearch and development day in more than a decade.
The company highlighted advanced and early-stage projects inrespiratory medicine, immunology, oncology, vaccines, HIV andother infections, and rare diseases.
(Reporting by Ben Hirschler; Editing by Keith Weir)